Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma

about

Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma

Item

http://www.wikidata.org/entity/Q58693750

description

im September 2018 veröffentlichter wissenschaftlicher Artikel

@de

scientific article published on 26 September 2018

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована у вересні 2018

@uk

name

Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma

@en

Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma

@nl

type

Item

label

Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma

@en

Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma

@nl

prefLabel

Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma

@en

Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma

@nl

P1476

Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma

@en

P2093

Andre Fay

http://www.w3.org/2001/XMLSchema#string

Barbara Ogórek

http://www.w3.org/2001/XMLSchema#string

Damir Khabibullin

http://www.w3.org/2001/XMLSchema#string

Daniel Rosebrock

http://www.w3.org/2001/XMLSchema#string

David F McDermott

http://www.w3.org/2001/XMLSchema#string

Dimitri Livitz

http://www.w3.org/2001/XMLSchema#string

Lana Hamieh

http://www.w3.org/2001/XMLSchema#string

Neeraj Agarwal

http://www.w3.org/2001/XMLSchema#string

Sabina Signoretti

http://www.w3.org/2001/XMLSchema#string

Wenhua Gao

http://www.w3.org/2001/XMLSchema#string

P2860

The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis

Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Comprehensive molecular characterization of clear cell renal cell carcinoma.

Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.

A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity.

Response and acquired resistance to everolimus in anaplastic thyroid cancer

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

P304

e1007679

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PGEN.1007679

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jean-Christophe Pignon

Toni K Choueiri

David J Kwiatkowski

P577

2018-09-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30256787

http://www.w3.org/2001/XMLSchema#string

P921

cancer research

molecular biology

P932

6181431

http://www.w3.org/2001/XMLSchema#string